Xvivo Perfusion AB
STO:XVIVO
Intrinsic Value
Xvivo Perfusion AB is a medical technology company. [ Read More ]
The intrinsic value of one
XVIVO
stock under the Base Case scenario is
180.28
SEK.
Compared to the current market price of 381.5 SEK,
Xvivo Perfusion AB
is
Overvalued by 53%.
XVIVO's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
XVIVO or that its price is influenced by factors unrelated to fundamentals.
Xvivo Perfusion AB's market capitalization is 12B SEK.
XVIVO stock price is 381.5 SEK.
XVIVO stock (180.28 SEK) is 53% less than its price (381.5 SEK).
XVIVO stock (194.14 SEK) is 49% less than its price (381.5 SEK). Open DCF Valuation
XVIVO stock (166.42 SEK) is 56% less than its price (381.5 SEK). Open Relative Valuation
XVIVO has upside potential of 11% compared to the average analyst price target.
Open Wall St Estimates
XVIVO's ROE (Return on Equity) for the past 12 months is positive and is equal to 6%.
XVIVO's ROIC (Return on Invested Capital) has increased in the last 3 years from -5% to 1%.
XVIVO's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 1%.
XVIVO's Revenue has grown by an exceptional 39% over the past 12 months.
XVIVO's ROE (Return on Equity) has significantly increased in the last 3 years from -5% to 6%.
XVIVO has positive Net Income for the last twelve months.
XVIVO has positive Operating Income for the last twelve months.
XVIVO has a very low three-year average ROE (Return on Equity): 1%. The company is not efficient at transforming stockholders' equity into net income.
XVIVO's Revenue is forecast to grow at a rate of 33% per year over the next 3 years.
XVIVO has negative three-year average ROIC (Return on Invested Capital): -1%. The company is not efficient at using invested capital to generate operating income.
XVIVO has positive Gross Profit for the last twelve months.
XVIVO has positive Free Cash Flow for the last twelve months.
XVIVO's Revenue has been growing by an exceptional 50% per year for the last 3 years.
XVIVO's D/E (Debt to Equity) is very low and is equal to 0.01.
XVIVO's short-term assets (831m SEK) exceed its short-term liabilties (200m SEK).
XVIVO's long-term assets (2B SEK) exceed its long-term liabilties (251m SEK).
XVIVO has negative Net Debt. This means that the company has more cash and short-term investments (511m SEK) than debt (20m SEK).
XVIVO's Altman Z-Score is very high and is equal to 21.26.
Valuation Backtest
Xvivo Perfusion AB
Run backtest to discover the historical profit from buying and selling
XVIVO
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Xvivo Perfusion AB
Balance Sheet Decomposition
Xvivo Perfusion AB
| Current Assets | 830.7m |
| Cash & Short-Term Investments | 511.2m |
| Receivables | 168.6m |
| Other Current Assets | 151m |
| Non-Current Assets | 1.4B |
| Long-Term Investments | 45.2m |
| PP&E | 110.1m |
| Intangibles | 1.3B |
| Current Liabilities | 199.8m |
| Other Current Liabilities | 199.8m |
| Non-Current Liabilities | 50.7m |
| Long-Term Debt | 19.9m |
| Other Non-Current Liabilities | 30.8m |
Earnings Waterfall
Xvivo Perfusion AB
|
Revenue
|
642.9m
SEK
|
|
Cost of Revenue
|
-167.5m
SEK
|
|
Gross Profit
|
475.4m
SEK
|
|
Operating Expenses
|
-463.4m
SEK
|
|
Operating Income
|
12m
SEK
|
|
Other Expenses
|
88.5m
SEK
|
|
Net Income
|
100.4m
SEK
|
Free Cash Flow Analysis
Xvivo Perfusion AB
XVIVO Profitability Score
Profitability Due Diligence
Xvivo Perfusion AB's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
Xvivo Perfusion AB's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
XVIVO Solvency Score
Solvency Due Diligence
Xvivo Perfusion AB's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Xvivo Perfusion AB's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
XVIVO Price Targets Summary
Xvivo Perfusion AB
According to Wall Street analysts, the average 1-year price target for
XVIVO
is 423.91 SEK
with a low forecast of 343.4 SEK and a high forecast of 491.4 SEK.
Shareholder Return
XVIVO Price
Xvivo Perfusion AB
| Average Annual Return | 7.84% |
| Standard Deviation of Annual Returns | 50.18% |
| Max Drawdown | -71% |
| Market Capitalization | 12B SEK |
| Shares Outstanding | 31 499 470 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Xvivo Perfusion AB
Country
Industry
Market Cap
Dividend Yield
Description
Xvivo Perfusion AB is a medical technology company. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 92 full-time employees. The company went IPO on 2012-10-08. The firm operates in two segments: Durable goods and Non-Durable goods. The Durable goods segment comprises sale and rental income from XVIVO Perfusion System (XPS) machines. The Non-Durable goods segment implies revenue from the sale of products and services that are solutions and disposable items. The Company’s product portfolio consists of Perfadex, STEEN Solution, XPS, XPS Disposable Kit, XVIVO Lung Cannula Set, XVIVO Organ Chamber, XPS PGM Disposable Sensors and Silicone Tubing Set. The firm markets its products in Europe, Asia, Middle East, and North & South America.
Contact
IPO
Employees
Officers
The intrinsic value of one
XVIVO
stock under the Base Case scenario is
180.28
SEK.
Compared to the current market price of 381.5 SEK,
Xvivo Perfusion AB
is
Overvalued by 53%.
You don't have any saved screeners yet
